| Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation S Kapoor, K Natarajan, PR Baldwin, KA Doshi, RG Lapidus, TJ Mathias, ... Clinical Cancer Research 24 (1), 234-247, 2018 | 36 | 2018 |
| The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant … TJ Mathias, K Natarajan, S Shukla, KA Doshi, ZN Singh, SV Ambudkar, ... Investigational new drugs 33, 300-309, 2015 | 24 | 2015 |
| Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress KA Doshi, R Trotta, K Natarajan, FV Rassool, AE Tron, D Huszar, ... Oncotarget 7 (30), 48280, 2016 | 18 | 2016 |
| Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach J Candia, S Cherukuri, Y Guo, KA Doshi, JR Banavar, CI Civin, W Losert Convergent science physical oncology 1 (2), 025002, 2015 | 9 | 2015 |
| Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer C Vergato, KA Doshi, D Roblyer, DJ Waxman Cancer Research Communications 2 (4), 246-257, 2022 | 4 | 2022 |
| Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included. B Alaybeyoglu, HW Cheng, KA Doshi, V Makani, AM Stein Journal of Pharmacokinetics and Pharmacodynamics 48, 447-464, 2021 | 4 | 2021 |
| The clinically applicable pan-Pim kinase inhibitor PIM447 sensitizes acute myeloid leukemia cells with FLT3-ITD to induction of apoptosis by FLT3 inhibitors and by … KA Doshi, PR Baldwin, S Kapoor, MR Baer Cancer Research 76 (14_Supplement), 3866-3866, 2016 | 3 | 2016 |
| Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 … M Scarpa, S Kapoor, ES Tvedte, KA Doshi, YS Zou, P Singh, JK Lee, ... Oncotarget 12 (18), 1763, 2021 | 2 | 2021 |
| Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancer V Cameron, D Kshama A, R Darren, W David J BioRxiv, 2021 | 2 | 2021 |
| SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti … M Panduro, RM Dornbrook, KA Doshi, J Hua, J Strand, VJ Palombella, ... Cancer Research 80 (16_Supplement), 4548-4548, 2020 | 2 | 2020 |
| The pim kinase inhibitor AZD1208 enhances apoptosis induction by clinically active FLT3 inhibitors in FLT3-ITD acute myeloid leukemia cells in vitro and in vivo through … K Natarajan, TJ Mathias, KA Doshi, AE Tron, M Kraus, R Trotta, D Perrotti, ... Blood 124 (21), 3601, 2014 | 2 | 2014 |
| Uncovering differential multi-microRNA signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-based network approach J Candia, S Cherukuri, KA Doshi, JR Banavar, CI Civin, W Losert Press, 2014 | 2 | 2014 |
| The Pim kinase inhibitor AZD1208 sensitizes acute myeloid leukemia cells with fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) to cytotoxic effects of … KA Doshi, K Natarajan, B Wolfson, D Huszar, MR Baer Cancer Research 75 (15_Supplement), 5332-5332, 2015 | 1 | 2015 |
| Anti-FolRα ADC STRO-002 induces immunogenic cell death (ICD) to enhance anti-tumor activity C Abrahams, A McGeehan, J Smith, R Yuan, KA Doshi, S Zhou, X Li, ... Cancer Research 82 (12), 2022 | | 2022 |
| Half-life extended, conditionally active IFNα prodrug induces tumor-selective activation and potent anti-tumor response KB Alice Yam, Kshama A. Doshi, Krishna Bajjuri, Millicent Embry, Alan Nguyen ... Journal of Immunotherapy for Cancer, 2022 | | 2022 |
| The anti-CD47 antibody SRF231 increases anti-tumor activity of standard of care chemotherapy in platinum-resistant PDX models of ovarian cancer JF Liu, KA Doshi, BH Lee, MO Peluso, L Zhang, S Zhou, Q Zeng, S Wang, ... Cancer Research 80 (16_Supplement), 4515-4515, 2020 | | 2020 |
| SRF231, a fully human CD47 antibody, potentiates the effects of opsonizing antibodies and cytotoxic chemotherapies in preclinical cancer models KA Doshi, M Rausch, CM Armet, L Zhang, AM Paterson, BH Lee, ... Curr Opin Immunol 24, 225-32, 2020 | | 2020 |
| SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a M Peluso, KA Doshi, C Armet, L Zhang, R O'Connor, M Rausch, J Hill, ... Journal for Immunotherapy of Cancer 7 (282), 147, 2019 | | 2019 |
| Towards in vivo preclinical monitoring of multiscale vascular structure-function relationships in resistant breast cancers with an integrated diffuse and nonlinear imaging … K Karrobi, A Pilvar, A Tank, K Doshi, DJ Waxman, D Roblyer Multimodal Biomedical Imaging XIV 10871, 108710E, 2019 | | 2019 |
| Elucidating the functional role of type-1 interferon signaling following a medium-dose intermittent cyclophosphamide schedule in preclinical breast cancer models KA Doshi, C Vergato, D Roblyer, DJ Waxman Journal for Immunotherapy of Cancer 6 (115), 236, 2018 | | 2018 |
